Ivaltinostat

Phase 2

00%

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

4mo

CGONPhase 2$3.0B

Ivaltinostat Phase 2 Results Expected

Ivaltinostat• Metastatic Pancreatic Adenocarcinoma70

Jun 15Estimated

00%

Competitive Landscape

2 competitors in Metastatic Pancreatic Adenocarcinoma

Drug Information

Target Indication

Metastatic Pancreatic Adenocarcinoma

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

CGON

CG Oncology, Inc.

Related Pipeline

High-Risk Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer